{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:08Z","timestamp":1790916968245,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1245\/s10434-026-20133-1","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:51:37Z","timestamp":1783680697000},"page":"9772-9779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Practice Patterns and Overall Survival for Octogenarians with Triple Negative Breast Cancer Treated at Accredited Cancer Centers in the USA"],"prefix":"10.1245","volume":"33","author":[{"given":"Alexandra L.","family":"Mathews","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Kopkash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecylia","family":"Mizera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"20133_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-20301-6_1","volume":"1152","author":"A Ahmad","year":"2019","unstructured":"Ahmad A. Breast cancer statistics: recent trends. Adv Exp Med Biol. 2019;1152:1\u20137.","journal-title":"Adv Exp Med Biol"},{"key":"20133_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/tbj.12813","volume":"23","author":"HG Kaplan","year":"2017","unstructured":"Kaplan HG, Malmgren JA, Atwood MK. Triple-negative breast cancer in the elderly: prognosis and treatment. Breast J. 2017;23:630\u20137.","journal-title":"Breast J"},{"key":"20133_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds189","author":"M Aapro","year":"2012","unstructured":"Aapro M, Wildiers H. Triple-negative breast cancer in the older population. Ann Oncol. 2012. https:\/\/doi.org\/10.1093\/annonc\/mds189.","journal-title":"Ann Oncol"},{"key":"20133_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10549-024-07309-7","volume":"207","author":"A Singareeka Raghavendra","year":"2024","unstructured":"Singareeka Raghavendra A, Liu D, Shen Y, et al. Outcomes of older adults with early-stage triple-negative breast cancer (TNBC) receiving chemotherapy: a single-institution experience. Breast Cancer Res Treat. 2024;207:81\u201390.","journal-title":"Breast Cancer Res Treat"},{"key":"20133_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejso.2020.09.022","volume":"47","author":"Y Jauhari","year":"2021","unstructured":"Jauhari Y, Dodwell D, Gannon MR, et al. The influence of age, comorbidity and frailty on treatment with surgery and systemic therapy in older women with operable triple negative breast cancer (TNBC) in England: a population-based cohort study. Eur J Surg Oncol. 2021;47:251\u201360.","journal-title":"Eur J Surg Oncol"},{"key":"20133_CR6","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1245\/s10434-007-9747-3","volume":"15","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15:683\u201390.","journal-title":"Ann Surg Oncol"},{"key":"20133_CR7","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613\u2013961.","journal-title":"J Clin Epidemiol"},{"key":"20133_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaf049","author":"B Ahmed","year":"2025","unstructured":"Ahmed B, Al-Khames Aga Q, Cheung KL, et al. Treatment strategies for triple-negative primary breast cancer in older women: a systematic review. JNCI Cancer Spectr. 2025. https:\/\/doi.org\/10.1093\/jncics\/pkaf049.","journal-title":"JNCI Cancer Spectr"},{"key":"20133_CR9","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/S1470-2045(20)30538-6","volume":"21","author":"JA Crozier","year":"2020","unstructured":"Crozier JA, Pezzi TA, Hodge C, et al. Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis. Lancet Oncol. 2020;21:1611\u20139.","journal-title":"Lancet Oncol"},{"key":"20133_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-7568(20)30018-0","author":"S Janeva","year":"2020","unstructured":"Janeva S, Zhang C, Kov\u00e1cs A, et al. Adjuvant chemotherapy and survival in women aged 70 years and older with triple-negative breast cancer: a Swedish population-based propensity score-matched analysis. Lancet Healthy Longev. 2020. https:\/\/doi.org\/10.1016\/S2666-7568(20)30018-0.","journal-title":"Lancet Healthy Longev"},{"key":"20133_CR11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2026.5061","author":"JD Anampa","year":"2026","unstructured":"Anampa JD, Avila J, Brodsky M, et al. Adjuvant chemotherapy outcomes in older adults with nonmetastatic triple-negative breast cancer. JAMA Netw Open. 2026. https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.5061.","journal-title":"JAMA Netw Open"},{"key":"20133_CR12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810\u201321.","journal-title":"N Engl J Med"},{"key":"20133_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-026-00919-y","author":"MC Gouveia","year":"2026","unstructured":"Gouveia MC, Barroso-Sousa R, Lapuchesky L, et al. Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real\/GBECAM-0123. NPJ Breast Cancer. 2026. https:\/\/doi.org\/10.1038\/s41523-026-00919-y.","journal-title":"NPJ Breast Cancer"},{"key":"20133_CR14","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-P5-11-16","author":"N Polidorio","year":"2025","unstructured":"Polidorio N, Perry LM, Veeravalli SS, et al. Abstract P5\u201311-16: Outcomes in elderly patients with triple-negative breast cancer receiving neoadjuvant chemo-immunotherapy and chemotherapy alone. Clin Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1557-3265.SABCS24-P5-11-16.","journal-title":"Clin Cancer Res"},{"key":"20133_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ctrv.2015.11.009","volume":"43","author":"L Biganzoli","year":"2016","unstructured":"Biganzoli L, Aapro M, Loibl S, Wildiers H, Brain E. Taxanes in the treatment of breast cancer: have we better defined their role in older patients? A position paper from a SIOG Task Force. Cancer Treat Rev. 2016;43:19\u201326.","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 4","key":"20133_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.6004\/jnccn.2008.2004","volume":"6","author":"RW Carlson","year":"2008","unstructured":"Carlson RW, Moench S, Hurria A, et al. NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008;6(Suppl 4):S1-27.","journal-title":"J Natl Compr Canc Netw"},{"key":"20133_CR17","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1200\/JCO.19.00647","volume":"37","author":"HB Muss","year":"2019","unstructured":"Muss HB, Polley MYC, Berry DA, et al. Randomized trial of standard adjuvant chemotherapy regimens versus capecitabine in older women with early breast cancer: 10-year update of the CALGB 49907 trial. J Clin Oncol. 2019;37:2338\u201348.","journal-title":"J Clin Oncol"},{"key":"20133_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10549-021-06424-z","volume":"191","author":"AR Schreiber","year":"2022","unstructured":"Schreiber AR, Kagihara J, Eguchi M, et al. Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study. Breast Cancer Res Treat. 2022;191:389\u201399.","journal-title":"Breast Cancer Res Treat"},{"key":"20133_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ejca.2023.02.014","volume":"185","author":"S Roy","year":"2023","unstructured":"Roy S, Lakritz S, Schreiber AR, et al. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: a SEER\u2013Medicare study. Eur J Cancer. 2023;185:69\u201382.","journal-title":"Eur J Cancer"},{"key":"20133_CR20","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1200\/JCO.20.02063","volume":"39","author":"A Magnuson","year":"2021","unstructured":"Magnuson A, Sedrak MS, Gross CP, et al. Development and validation of a risk tool for predicting severe toxicity in older adults receiving chemotherapy for early-stage breast cancer. J Clin Oncol. 2021;39:608\u201318.","journal-title":"J Clin Oncol"},{"key":"20133_CR21","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018;36:2326\u201347.","journal-title":"J Clin Oncol"},{"key":"20133_CR22","unstructured":"Guidelines Detail, Older Adult Oncology. NCCN. Accessed May 16, 2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=4&id=1452"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20133-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20133-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:50:36Z","timestamp":1790916636000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20133-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20133"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20133-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nothing to disclose.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}